EI24 | Etoposide induced 2.4 | Cancer-related genes Disease related genes Potential drug targets Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Expressed in all |
ELOVL1 | ELOVL fatty acid elongase 1 | Enzymes Predicted membrane proteins
| | | | | Expressed in all |
FITM1 | Fat storage-inducing transmembrane protein 1 | Predicted membrane proteins
| | | | | Group enriched |
FLVCR2 | Feline leukemia virus subgroup C cellular receptor family, member 2 | Disease related genes Potential drug targets Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Mixed |
FRRS1 | Ferric-chelate reductase 1 | Predicted membrane proteins
| | | | | Mixed |
GDPD2 | Glycerophosphodiester phosphodiesterase domain containing 2 | Cytoskeleton related proteins Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
GDPD5 | Glycerophosphodiester phosphodiesterase domain containing 5 | Predicted membrane proteins
| | | | | Expressed in all |
GGCX | Gamma-glutamyl carboxylase | Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins
| | | | | Expressed in all |
GHITM | Growth hormone inducible transmembrane protein | Predicted membrane proteins
| | | | | Expressed in all |
GHSR | Growth hormone secretagogue receptor | Disease related genes G-protein coupled receptors Potential drug targets Predicted membrane proteins Transporters
| | | | | Not detected |
GPER1 | G protein-coupled estrogen receptor 1 | G-protein coupled receptors Predicted membrane proteins Predicted secreted proteins
| | | | | Mixed |
GPR137 | G protein-coupled receptor 137 | Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enriched |
GPR137C | G protein-coupled receptor 137C | Predicted membrane proteins
| | | | | Group enriched |
GPR149 | G protein-coupled receptor 149 | G-protein coupled receptors Predicted membrane proteins
| | | | | Not detected |
GPR153 | G protein-coupled receptor 153 | G-protein coupled receptors Predicted membrane proteins
| | | | | Mixed |
GPR157 | G protein-coupled receptor 157 | G-protein coupled receptors Predicted membrane proteins
| | | | | Group enriched |
GPR31 | G protein-coupled receptor 31 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
GPR39 | G protein-coupled receptor 39 | G-protein coupled receptors Predicted membrane proteins
| | | | | Mixed |
GPR78 | G protein-coupled receptor 78 | G-protein coupled receptors Predicted membrane proteins
| | | | | Not detected |
GPR83 | G protein-coupled receptor 83 | G-protein coupled receptors Plasma proteins Predicted membrane proteins
| | | | | Group enriched |
GRINA | Glutamate receptor, ionotropic, N-methyl D-aspartate-associated protein 1 (glutamate binding) | Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
HGSNAT | Heparan-alpha-glucosaminide N-acetyltransferase | Disease related genes Enzymes Potential drug targets Predicted membrane proteins
| | | | | Expressed in all |
HM13 | Histocompatibility (minor) 13 | Enzymes Plasma proteins Predicted membrane proteins
| | | | | Expressed in all |
ICMT | Isoprenylcysteine carboxyl methyltransferase | Enzymes Plasma proteins Predicted membrane proteins
| | | | | Expressed in all |
INSIG2 | Insulin induced gene 2 | Predicted membrane proteins
| | | | | Expressed in all |
ITPR2 | Inositol 1,4,5-trisphosphate receptor, type 2 | Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Mixed |
JKAMP | JNK1/MAPK8-associated membrane protein | Cancer-related genes Predicted membrane proteins
| | | | | Expressed in all |
KCNA1 | Potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) | Disease related genes FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNA10 | Potassium voltage-gated channel, shaker-related subfamily, member 10 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Not detected |
KCNA2 | Potassium voltage-gated channel, shaker-related subfamily, member 2 | FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
KCNA3 | Potassium voltage-gated channel, shaker-related subfamily, member 3 | FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
KCNA4 | Potassium voltage-gated channel, shaker-related subfamily, member 4 | FDA approved drug targets Plasma proteins Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNB1 | Potassium voltage-gated channel, Shab-related subfamily, member 1 | FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNC1 | Potassium voltage-gated channel, Shaw-related subfamily, member 1 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNC2 | Potassium voltage-gated channel, Shaw-related subfamily, member 2 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNC3 | Potassium voltage-gated channel, Shaw-related subfamily, member 3 | Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
KCND1 | Potassium voltage-gated channel, Shal-related subfamily, member 1 | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Voltage-gated ion channels
| | | | | Mixed |
KCND2 | Potassium voltage-gated channel, Shal-related subfamily, member 2 | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCND3 | Potassium voltage-gated channel, Shal-related subfamily, member 3 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
KCNH1 | Potassium voltage-gated channel, subfamily H (eag-related), member 1 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNH5 | Potassium voltage-gated channel, subfamily H (eag-related), member 5 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNH6 | Potassium voltage-gated channel, subfamily H (eag-related), member 6 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNH7 | Potassium voltage-gated channel, subfamily H (eag-related), member 7 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNK1 | Potassium channel, subfamily K, member 1 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Mixed |
KCNK10 | Potassium channel, subfamily K, member 10 | Predicted membrane proteins
| | | | | Tissue enhanced |
KCNK13 | Potassium channel, subfamily K, member 13 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNK16 | Potassium channel, subfamily K, member 16 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
KCNK17 | Potassium channel, subfamily K, member 17 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
KCNK18 | Potassium channel, subfamily K, member 18 | Disease related genes Potential drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Not detected |
KCNK2 | Potassium channel, subfamily K, member 2 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |